Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MHLW Minister Says Pharmaceuticals Companies Should Apologize For Hepatitis C Victims

This article was originally published in PharmAsia News

Executive Summary

The compensation package for hepatitis C patients who used contaminated blood products takes effect on January 16. At a press briefing announcing the news, Japan's Minister of Health, Labor and Welfare Yoichi Masuzoe pointed out that the primary responsibility lies with drug makers, and they should reflect on their roles in the contaminations and apologize. "I expect them to take appropriate responsibilities since the drug makers are not included in the basic agreement package," Masuzoe said. He also urged the pharmaceutical companies to work with the government to resolve the problem.Regarding the compensation cost share by the government and drug companies, Masuzoe said drug companies should contribute two-thirds of the cost, and the government should cover one-third, but concrete numbers are still in negotiations. (Click here for more

You may also be interested in...

QUOTED. 22 October. Robert Ford.

Abbott reported third-quarter 2020 global sales of $8.9bn, driven by its strong position in COVID-19 tests. See what Abbott’s CEO Robert Ford said about it here.

China Regulatory Express: Biosecurity Law, Export Controls And The Life Science Sector

With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.

Mediocre Vaccine Could Make Pandemic Worse, Non-Profit Group Tells US FDA

Ahead of the vaccine advisory committee, requests to FDA range from public health groups opposing emergency use authorizations to industry seeking labeling guidance on EUA products.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts